Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Electron transfer flavoprotein beta subunit lysine methyltransferase (ETFBKMT, also known as METTL20) is a mitochondrial enzyme that specifically trimethylates lysine residues on the beta subunit of electron transfer flavoprotein (ETFB). This posttranslational modification can negatively regulate ETFB’s function in electron transfer from acyl-CoA dehydrogenases to the respiratory chain, thus modulating mitochondrial fatty acid oxidation and energy metabolism. Genetic variants in ETFBKMT are associated with metabolic disorders such as multiple acyl-CoA dehydrogenase deficiency, which impacts mitochondrial fatty acid and amino acid catabolism. The protein is also involved in pathways related to protein methylation and has a paralog, HEMK1. Currently, no direct drugs are approved or known to target ETFBKMT, and there are no established biomarkers or safety issues specifically associated with this enzyme in clinical contexts.
Catalytic methylation of lysine residues on ETFB, regulating its function in the mitochondrial electron transfer chain
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Electron transfer flavoprotein beta subunit lysine methyltransferase (ETFBKMT).